Skip to main content
Top
Published in: Inflammation 1/2017

01-02-2017 | ORIGINAL ARTICLE

Distinct Secretory Activity and Clinical Impact of Subcutaneous Abdominal Adipose Tissue in Women with Rheumatoid Arthritis and Osteoarthritis

Authors: Ewa Kontny, Agnieszka Zielińska, Urszula Skalska, Krystyna Księżopolska-Orłowska, Piotr Głuszko, Włodzimierz Maśliński

Published in: Inflammation | Issue 1/2017

Login to get access

Abstract

In the general population, low-grade inflammation of adipose tissue accompanies obesity and contributes to cardiovascular disease (CVD) development, but the implication of this tissue in rheumatic disease pathology is unclear. Therefore, we characterized the secretory activity of subcutaneous abdominal adipose tissue (SAAT) of females with rheumatoid arthritis (RA) and osteoarthritis (OA) and searched for its relationship with intensity of systemic inflammation, body composition and comorbidity. The secretion of classical adipokines (leptin, adiponectin), pro- and anti-inflammatory factors, i.e. interleukin (IL)-6, IL-8, IL-10, tumour necrosis factor (TNF), macrophage migration inhibitory factor (MIF) and hepatocyte growth factor (HGF), from SAAT explants was measured by specific enzyme-linked immunosorbent assays. Patients’ body composition was evaluated by bioelectric impendence technique. Rheumatoid SAAT secreted more adiponectin, IL-6, IL-10, TNF and MIF but less leptin than respective osteoarthritis tissues. In RA patients, TNF secretion correlated with cachectic body composition, HGF release was linked to secondary amyloidosis and visceral fat rating was an independent risk factor for CVD. In OA, secretion of leptin and HGF positively, while adiponectin inversely, correlated with systemic inflammation markers, and the release of MIF was an independent risk factor for CVD. This study reveals differences between RA and OA patients in SAAT secretory activity and suggests its different clinical impact in these diseases, characterized by high- and low-grade systemic inflammation, respectively. In RA, SAAT may directly or via an effect on body composition contribute to amyloidosis, cachexia or CVD co-occurring, while in OA SAAT-derived adipocytokines may rather regulate intensity of systemic inflammation and redound to CVD emergence.
Literature
1.
go back to reference Boissier, M.C., L. Semerano, S. Challal, N. Saidenberg-Kermanac’h, and D. Falgarone. 2012. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity 39: 222–228.CrossRefPubMed Boissier, M.C., L. Semerano, S. Challal, N. Saidenberg-Kermanac’h, and D. Falgarone. 2012. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity 39: 222–228.CrossRefPubMed
2.
go back to reference Cutolo, M., G.D. Kitas, and P.L. van Riel. 2014. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Seminars in Arthritis and Rheumatism 43: 479–488.CrossRefPubMed Cutolo, M., G.D. Kitas, and P.L. van Riel. 2014. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Seminars in Arthritis and Rheumatism 43: 479–488.CrossRefPubMed
3.
go back to reference Berenbaum, F. 2013. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis). Osteoarthritis and Cartilage 21: 16–21.CrossRefPubMed Berenbaum, F. 2013. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis). Osteoarthritis and Cartilage 21: 16–21.CrossRefPubMed
4.
go back to reference van Dijk, G.M., C. Veenhof, F. Schellevis, H. Hulsmans, J.P. Bakker, H. Arwent, J.H. Dekker, G.J. Lankhorst, and J. Dekker. 2008. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskeletal Disorders 9: 95.CrossRefPubMedPubMedCentral van Dijk, G.M., C. Veenhof, F. Schellevis, H. Hulsmans, J.P. Bakker, H. Arwent, J.H. Dekker, G.J. Lankhorst, and J. Dekker. 2008. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskeletal Disorders 9: 95.CrossRefPubMedPubMedCentral
5.
go back to reference Johnson, V.L., and D.J. Hunter. 2014. The epidemiology of osteoarthritis. Best Practice and Research Clinical Rheumatology 28: 5–15.CrossRefPubMed Johnson, V.L., and D.J. Hunter. 2014. The epidemiology of osteoarthritis. Best Practice and Research Clinical Rheumatology 28: 5–15.CrossRefPubMed
6.
go back to reference Pottie, P., N. Presle, B. Terlain, P. Netter, D. Mainard, and F. Berenbaum. 2006. Obesity and osteoarthritis: more complex than predicted! Annals of the Rheumatic Diseases 65: 1403–1405.CrossRefPubMedPubMedCentral Pottie, P., N. Presle, B. Terlain, P. Netter, D. Mainard, and F. Berenbaum. 2006. Obesity and osteoarthritis: more complex than predicted! Annals of the Rheumatic Diseases 65: 1403–1405.CrossRefPubMedPubMedCentral
7.
go back to reference Versini, M., P.Y. Jeandel, E. Rosenthal, and Y. Shoenfeld. 2014. Obesity in autoimmune diseases: not a passive bystander. Autoimmunity Reviews 13: 981–1000.CrossRefPubMed Versini, M., P.Y. Jeandel, E. Rosenthal, and Y. Shoenfeld. 2014. Obesity in autoimmune diseases: not a passive bystander. Autoimmunity Reviews 13: 981–1000.CrossRefPubMed
8.
go back to reference Summers, G.D., C.M. Deighton, M.J. Rennie, and A.H. Booth. 2008. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47: 1124–1131.CrossRef Summers, G.D., C.M. Deighton, M.J. Rennie, and A.H. Booth. 2008. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47: 1124–1131.CrossRef
10.
go back to reference Galic, S., J.S. Oakhill, and G.R. Steinberg. 2010. Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology 316: 129–139.CrossRefPubMed Galic, S., J.S. Oakhill, and G.R. Steinberg. 2010. Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology 316: 129–139.CrossRefPubMed
11.
go back to reference Gustafson, B. 2010. Adipose tissue, inflammation and atherosclerosis. Journal of Atherosclerosis and Thrombosis 17: 332–341.CrossRefPubMed Gustafson, B. 2010. Adipose tissue, inflammation and atherosclerosis. Journal of Atherosclerosis and Thrombosis 17: 332–341.CrossRefPubMed
12.
go back to reference Lee, M.J., Y. Wu, and S.K. Fried. 2013. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Molecular Aspects of Medicine 34: 1–11.CrossRefPubMed Lee, M.J., Y. Wu, and S.K. Fried. 2013. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Molecular Aspects of Medicine 34: 1–11.CrossRefPubMed
13.
go back to reference White, U., and Y.D. Tchoukalova. 2014. Sex dimorphism and depot differences in adipose tissue function. Biochimica et Biophysica Acta 1842: 377–392.CrossRefPubMed White, U., and Y.D. Tchoukalova. 2014. Sex dimorphism and depot differences in adipose tissue function. Biochimica et Biophysica Acta 1842: 377–392.CrossRefPubMed
14.
go back to reference Kontny, E., M. Plebanczyk, B. Lisowska, M. Olszewska, P. Maldyk, and W. Maslinski. 2012. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Annals of the Rheumatic Diseases 71: 262–267.CrossRefPubMed Kontny, E., M. Plebanczyk, B. Lisowska, M. Olszewska, P. Maldyk, and W. Maslinski. 2012. Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Annals of the Rheumatic Diseases 71: 262–267.CrossRefPubMed
15.
go back to reference Eymard, F., A. Pigenet, D. Citadelle, C.H. Flouzat-Lachaniette, A. Poignard, C. Benelli, F. Berenbaum, X. Chevalier, and X. Houard. 2014. Induction of an inflammatory and prodegenerative phenotype in autologous fibroblast-like synoviocytes by the infrapatellar fat pad from patients with knee osteoarthritis. Arthritis and Rheumatology 66: 2165–2174.CrossRefPubMed Eymard, F., A. Pigenet, D. Citadelle, C.H. Flouzat-Lachaniette, A. Poignard, C. Benelli, F. Berenbaum, X. Chevalier, and X. Houard. 2014. Induction of an inflammatory and prodegenerative phenotype in autologous fibroblast-like synoviocytes by the infrapatellar fat pad from patients with knee osteoarthritis. Arthritis and Rheumatology 66: 2165–2174.CrossRefPubMed
16.
go back to reference Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.CrossRefPubMed Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.CrossRefPubMed
17.
go back to reference Real de Asúa, D., R. Costa, J.M. Galván, M.T. Filigheddu, D. Trujillo, and J. Cadiñanos. 2014. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clinical Epidemiology 6: 369–377.CrossRefPubMedPubMedCentral Real de Asúa, D., R. Costa, J.M. Galván, M.T. Filigheddu, D. Trujillo, and J. Cadiñanos. 2014. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clinical Epidemiology 6: 369–377.CrossRefPubMedPubMedCentral
18.
go back to reference Sokolove, J., and C.M. Lepus. 2013. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Therapeutic Advances in Musculoskeletal Disease 5: 77–94.CrossRefPubMedPubMedCentral Sokolove, J., and C.M. Lepus. 2013. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Therapeutic Advances in Musculoskeletal Disease 5: 77–94.CrossRefPubMedPubMedCentral
19.
go back to reference Lee, B.C., and J. Lee. 2014. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochimica et Biophysica Acta 1842: 446–462.CrossRefPubMed Lee, B.C., and J. Lee. 2014. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochimica et Biophysica Acta 1842: 446–462.CrossRefPubMed
20.
go back to reference Kontny, E., and M. Prochorec-Sobieszek. 2013. Articular adipose tissue resident macrophages in rheumatoid arthritis patients: potential contribution to local abnormalities. Rheumatology (Oxford) 52: 2158–2167.CrossRef Kontny, E., and M. Prochorec-Sobieszek. 2013. Articular adipose tissue resident macrophages in rheumatoid arthritis patients: potential contribution to local abnormalities. Rheumatology (Oxford) 52: 2158–2167.CrossRef
21.
go back to reference Stavropoulos-Kalinoglou, A., G.S. Metsios, Y. Koutedakis, and G.D. Kitas. 2011. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 50: 450–462.CrossRef Stavropoulos-Kalinoglou, A., G.S. Metsios, Y. Koutedakis, and G.D. Kitas. 2011. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 50: 450–462.CrossRef
22.
go back to reference Šenolt, L., A. Kuklová, L.A. Cerezo, H. Hulejová, M. Filková, L. Bošanovská, O. Pecha, K. Pavelka, M. HaluzíK, and J. Vencovský. 2011. Adipokine profile is modulated in subcutaneous adipose tissue by TNFα inhibitors in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 70: 2054–2056.CrossRefPubMed Šenolt, L., A. Kuklová, L.A. Cerezo, H. Hulejová, M. Filková, L. Bošanovská, O. Pecha, K. Pavelka, M. HaluzíK, and J. Vencovský. 2011. Adipokine profile is modulated in subcutaneous adipose tissue by TNFα inhibitors in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 70: 2054–2056.CrossRefPubMed
23.
go back to reference Toussirot, E., L. Mourot, B. Dehecq, D. Wendling, É. Grandclément, and G. Dumoulin. 2014. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. European Journal of Nutrition 53: 951–961.CrossRefPubMed Toussirot, E., L. Mourot, B. Dehecq, D. Wendling, É. Grandclément, and G. Dumoulin. 2014. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. European Journal of Nutrition 53: 951–961.CrossRefPubMed
24.
go back to reference Baker, J.F., J. Von Feldt, S. Mostoufi-Moab, G. Noaiseh, E. Taratuta, W. Kim, and M.B. Leonard. 2014. Deficit in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care and Research 66: 1612–1618.CrossRefPubMedPubMedCentral Baker, J.F., J. Von Feldt, S. Mostoufi-Moab, G. Noaiseh, E. Taratuta, W. Kim, and M.B. Leonard. 2014. Deficit in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care and Research 66: 1612–1618.CrossRefPubMedPubMedCentral
25.
go back to reference Stofkova, A. 2009. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocrine Regulations 43: 157–168.PubMed Stofkova, A. 2009. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocrine Regulations 43: 157–168.PubMed
26.
go back to reference Adamopoulous, I.E., and N.A. Athanasou. 2006. Hepatocyte growth factor in normal and diseased bone and joint tissue. Current Rheumatology Reviews 2: 1–7. Adamopoulous, I.E., and N.A. Athanasou. 2006. Hepatocyte growth factor in normal and diseased bone and joint tissue. Current Rheumatology Reviews 2: 1–7.
27.
go back to reference Mabey, T., S. Honsawek, N. Saetan, Y. Poovorawan, A. Tanavalee, and P. Yuktanandana. 2014. Angiogenic cytokine expression profiles in plasma and synovial fluid of primary knee osteoarthritis. International Orthopaedics 38: 1885–1892.CrossRefPubMed Mabey, T., S. Honsawek, N. Saetan, Y. Poovorawan, A. Tanavalee, and P. Yuktanandana. 2014. Angiogenic cytokine expression profiles in plasma and synovial fluid of primary knee osteoarthritis. International Orthopaedics 38: 1885–1892.CrossRefPubMed
28.
go back to reference Mirpourian, M., M. Salesi, H. Abdolahi, Z. Faraizadegan, and H. Karimzadeh. 2014. The association of body mass index with disease activity and clinical response to combinational therapy in patients with rheumatoid arthritis. Journal of Research in Medical Sciences 19: 509–514.PubMedPubMedCentral Mirpourian, M., M. Salesi, H. Abdolahi, Z. Faraizadegan, and H. Karimzadeh. 2014. The association of body mass index with disease activity and clinical response to combinational therapy in patients with rheumatoid arthritis. Journal of Research in Medical Sciences 19: 509–514.PubMedPubMedCentral
29.
go back to reference Giles, J.T., M. Allison, R.S. Blumenthal, W. Post, A.C. Gelber, M. Petri, R. Tracy, M. Szklo, and J.M. Bathon. 2010. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis and Rheumatism 62: 3173–3182.CrossRefPubMedPubMedCentral Giles, J.T., M. Allison, R.S. Blumenthal, W. Post, A.C. Gelber, M. Petri, R. Tracy, M. Szklo, and J.M. Bathon. 2010. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis and Rheumatism 62: 3173–3182.CrossRefPubMedPubMedCentral
30.
go back to reference Nakamura, K., J.J. Fuster, and K. Walsh. 2014. Adipokines: a link between obesity and cardiovascular disease. Journal of Cardiology 63: 250–259.CrossRefPubMed Nakamura, K., J.J. Fuster, and K. Walsh. 2014. Adipokines: a link between obesity and cardiovascular disease. Journal of Cardiology 63: 250–259.CrossRefPubMed
31.
go back to reference Bag-Ozbek, A., and J.T. Giles. 2015. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Current Allergy and Asthma Reports 15: 497.CrossRefPubMed Bag-Ozbek, A., and J.T. Giles. 2015. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Current Allergy and Asthma Reports 15: 497.CrossRefPubMed
32.
go back to reference Morrison, M.C., and R. Kleemann. 2015. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. Frontiers in Immunology 6: 308.CrossRefPubMedPubMedCentral Morrison, M.C., and R. Kleemann. 2015. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. Frontiers in Immunology 6: 308.CrossRefPubMedPubMedCentral
33.
go back to reference Zenecke, A., J. Bernhagen, and C. Weber. 2009. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117: 1594–1602.CrossRef Zenecke, A., J. Bernhagen, and C. Weber. 2009. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117: 1594–1602.CrossRef
34.
go back to reference Benigni, F., T. Atsumi, T. Calandra, C. Metz, B. Echtenacher, T. Peng, and R. Bucala. 2000. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. Journal of Clinical Investigation 106: 1291–1300.CrossRefPubMedPubMedCentral Benigni, F., T. Atsumi, T. Calandra, C. Metz, B. Echtenacher, T. Peng, and R. Bucala. 2000. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. Journal of Clinical Investigation 106: 1291–1300.CrossRefPubMedPubMedCentral
35.
go back to reference Batista Jr., M.L., R.X. Neves, S.B. Peres, A.S. Yamashita, C.S. Shida, S.R. Farmer, and M. Seelaender. 2013. Heterogenous time-dependent response of adipose tissue during the development of cancer cachexia. Journal of Endocrinology 215: 363–373.CrossRef Batista Jr., M.L., R.X. Neves, S.B. Peres, A.S. Yamashita, C.S. Shida, S.R. Farmer, and M. Seelaender. 2013. Heterogenous time-dependent response of adipose tissue during the development of cancer cachexia. Journal of Endocrinology 215: 363–373.CrossRef
36.
go back to reference Nakamura, T., K. Saki, T. Nakamura, and K. Matsumoto. 2011. Hepatocyte growth factor twenty years on: much more than growth factor. Journal of Gastroenterology and Hepatology 26(Suppl 1): 188–202.CrossRefPubMed Nakamura, T., K. Saki, T. Nakamura, and K. Matsumoto. 2011. Hepatocyte growth factor twenty years on: much more than growth factor. Journal of Gastroenterology and Hepatology 26(Suppl 1): 188–202.CrossRefPubMed
37.
go back to reference Grandaunet, B., S.W. Syversen, M. Hoff, A. Sundan, G. Haugeberg, D. van Der Heijde, T.K. Kvien, and T. Standal. 2011. Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis and Rheumatism 63: 662–669.CrossRefPubMed Grandaunet, B., S.W. Syversen, M. Hoff, A. Sundan, G. Haugeberg, D. van Der Heijde, T.K. Kvien, and T. Standal. 2011. Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis and Rheumatism 63: 662–669.CrossRefPubMed
38.
go back to reference Konya, H., M. Miuchi, K. Satani, S. Matsutani, T. Tsunoda, Y. Yano, T. Katsuno, T. Hamaguchi, J. Miyagawa, and M. Namba. 2014. Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. World Journal of Diabetes 5: 678–688.CrossRefPubMedPubMedCentral Konya, H., M. Miuchi, K. Satani, S. Matsutani, T. Tsunoda, Y. Yano, T. Katsuno, T. Hamaguchi, J. Miyagawa, and M. Namba. 2014. Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. World Journal of Diabetes 5: 678–688.CrossRefPubMedPubMedCentral
39.
go back to reference Shikano, M., H. Kushimoto, H. Hasegawa, M. Tomita, M. Hasegawa, K. Murakami, and S. Kawashima. 2000. Usefulness of serum hepatocyte growth factor for the diagnosis of amyloidosis. Internal Medicine 39: 715–719.CrossRefPubMed Shikano, M., H. Kushimoto, H. Hasegawa, M. Tomita, M. Hasegawa, K. Murakami, and S. Kawashima. 2000. Usefulness of serum hepatocyte growth factor for the diagnosis of amyloidosis. Internal Medicine 39: 715–719.CrossRefPubMed
40.
go back to reference Nakamura, T. 2011. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clinical and Experimental Rheumatology 29: 850–857.PubMed Nakamura, T. 2011. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clinical and Experimental Rheumatology 29: 850–857.PubMed
41.
go back to reference Sporanova, J., S.N. Nystrom, and G.T. Westermark. 2008. AA-amyloidosis can be transferred by peripheral blood monocytes. PloS One 3: e3308.CrossRef Sporanova, J., S.N. Nystrom, and G.T. Westermark. 2008. AA-amyloidosis can be transferred by peripheral blood monocytes. PloS One 3: e3308.CrossRef
Metadata
Title
Distinct Secretory Activity and Clinical Impact of Subcutaneous Abdominal Adipose Tissue in Women with Rheumatoid Arthritis and Osteoarthritis
Authors
Ewa Kontny
Agnieszka Zielińska
Urszula Skalska
Krystyna Księżopolska-Orłowska
Piotr Głuszko
Włodzimierz Maśliński
Publication date
01-02-2017
Publisher
Springer US
Published in
Inflammation / Issue 1/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0459-3

Other articles of this Issue 1/2017

Inflammation 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.